New safety rules proposed for gene synthesis companies and buyers

What does this do?

The bill directs the Department of Commerce to set safety rules for companies that make or sell synthetic DNA/RNA and gene-synthesis machines. Companies would screen orders against a list of "sequences of concern," verify customers, report suspicious split orders, and undergo compliance audits. It also creates a "biotechnology governance sandbox" for testing new biosecurity tools and asks the White House science office to study and streamline federal biosecurity oversight.

Who does it affect?

Affects companies that synthesize DNA/RNA or sell synthesis equipment, research institutions and universities using federal grants, and federal biosecurity agencies. The general public is indirectly affected through reduced risk of dangerous biological agents.

Why does it matter?

Companies failing audits could lose certification or face lawsuits and fines, and federally funded researchers could only buy from compliant companies, potentially limiting supplier options.

What does it cost, and who pays?

• Failed audits risk losing certification
• Non-compliant firms face lawsuits, fines
• No fine amounts specified